Given the emerging evidence that the upregulation of MTs exerts protective effects against both obesity and steatohepatitis, targeting MTs pathways represents a promising therapeutic strategy for both obesity and MASLD. The gene discussed is TIMM8A; the disease is metabolic dysfunction-associated steatotic liver disease.